Known for their CRISPR Analytics Platform, powered by the CRISPR-Chip, CRISPR QC analyzes and optimizes aspects of CRISPR editing before cell work, enabling researchers to save valuable time, money, and resources.

The company has secured substantial funding from Xcellerant Ventures, a distinguished player in healthcare venture capital; the commitment signals a shared vision for advancing gene editing technologies.

CRISPR QC's CRISPR Analytics Platform provides comprehensive measurements and analysis around CRISPR activity, enabling scientists and researchers to optimize gene editing outcomes and ensure the highest levels of quality control. The platform is built on the company's proprietary CRISPR-Chip technology, which allows for direct, real-time measurement of CRISPR activity.